Docetaxel in the treatment of advanced non-small-cell lung cancer

被引：55

作者：

Saloustros, Emmanouel ^{[1
]}

Georgoulias, Vassilis ^{[1
]}

机构：

[1] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion 71110, Crete, Greece

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2008年 / 8卷 / 08期

关键词：

chemotherapy; docetaxel; non-small-cell lung cancer; taxane;

D O I：

10.1586/14737140.8.8.1207

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Systemic chemotherapy provides improvement in both survival and quality of life for patients with advanced non-small-cell lung cancer (NSCLC). Docetaxel is the only agent currently approved for both first- and second-line treatment of advanced NSCLC. Multiple randomized clinical trials have established the efficacy of platinum-docetaxel regimens for the first-line treatment of advanced NSCLC. Carboplatin-based regimens and nonplatinum combinations with docetaxel also have proven efficacy in first-line therapy. Combinations of docetaxel with various novel targeted agents have produced encouraging data in Phase II trials. This review article summarizes recent studies of docetaxel as a single agent and in combination regimens with cytotoxic or targeted therapies in the management of patients with advanced NSCLC.

引用

页码：1207 / 1222

页数：16